Growth Hormone
GHRP-6
Growth Hormone Releasing Peptide 6
Original ghrelin mimetic · stimulates GH and appetite
- FDA Status
- Not FDA-approved · Investigational
- Class
- Hexapeptide · ghrelin agonist
- Sequence
- His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
- Half-life
- ~30 min
Mechanism of action
- Ghrelin receptor agonism → pituitary GH release
- Strong appetite stimulation (vs ipamorelin selective)
- Mild cortisol and prolactin increase
- Cardiovascular protective in animal models
Research areas
- GH deficiency diagnostic stimulation
- Cachexia and appetite stimulation
- Cardiac protection (animal data)
- Investigational anti-aging applications
Evidence and clinical data
Older peptide with extensive Phase I/II data. Largely superseded by ipamorelin for clean GH stimulation. Still used in cachexia research.
Safety profile
Well-known side effects: hunger, water retention, mild prolactin/cortisol shifts. Generally safe for short-term use.
Why this peptide is trending in 2026: Lower price point keeps it in research community. Often the "starting peptide" for individuals exploring GH stimulation.
Educational use only. PeptideAdvance does not sell GHRP-6, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.